Please login to the form below

Not currently logged in
Email:
Password:

Lorbrena

This page shows the latest Lorbrena news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

In the same trial, the progression-free survival rate was not yet estimable for Lorbrena, compared to 9.3 months for Xalkori. ... The intracranial objective response rate was 82% in patients with measurable brain metastases, with a complete response rate

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...

Infographics